RPRX Royalty Pharma Earnings and EPS analysis

EPS in 2026 (TTM): $1.91

Last Report Period Date: Mar 31, 2026

As of June 2026, according to Royalty Pharma's latest financial report, the company's current EPS (TTM) is $1.91. In 2025, the company recorded an earnings per share (EPS) of $1.79, which represents a decrease compared to its EPS of $1.92 in 2024. Royalty Pharma's earnings per share for the quarterly report ending on Mar 31, 2026 was $0.67.

The annual EPS in 2025 was $1.79, a decrease of 6.8% from $1.92 in 2024. For the quarter ending Mar 31, 2026, the EPS was $0.67, showing a 21.8% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $1.91. In 2024, the annual EPS was $1.92, showing a decrease of 24.4% from 2023.

Royalty Pharma has recorded an increase in EPS of 21.8% over the last 12 months (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS growth rate of 161.6% per year over the past 3 years. Royalty Pharma had an average annual EPS growth rate of 6.3% over the last 5 years.